CA3210629A1 - Actinohivin variant polypeptides and related methods - Google Patents

Actinohivin variant polypeptides and related methods Download PDF

Info

Publication number
CA3210629A1
CA3210629A1 CA3210629A CA3210629A CA3210629A1 CA 3210629 A1 CA3210629 A1 CA 3210629A1 CA 3210629 A CA3210629 A CA 3210629A CA 3210629 A CA3210629 A CA 3210629A CA 3210629 A1 CA3210629 A1 CA 3210629A1
Authority
CA
Canada
Prior art keywords
polypeptide
cell
ovarian cancer
subject
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3210629A
Other languages
English (en)
French (fr)
Inventor
Nobuyuki Matoba
Matthew DENT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Louisville Research Foundation ULRF
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3210629A1 publication Critical patent/CA3210629A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3210629A 2021-03-04 2022-03-04 Actinohivin variant polypeptides and related methods Pending CA3210629A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156715P 2021-03-04 2021-03-04
US63/156,715 2021-03-04
PCT/US2022/070961 WO2022187851A1 (en) 2021-03-04 2022-03-04 Actinohivin variant polypeptides and related methods

Publications (1)

Publication Number Publication Date
CA3210629A1 true CA3210629A1 (en) 2022-09-09

Family

ID=83155364

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3210629A Pending CA3210629A1 (en) 2021-03-04 2022-03-04 Actinohivin variant polypeptides and related methods

Country Status (9)

Country Link
US (1) US20240123026A1 (https=)
EP (1) EP4301389A4 (https=)
JP (1) JP2024509385A (https=)
CN (1) CN117098545A (https=)
AU (1) AU2022229597A1 (https=)
CA (1) CA3210629A1 (https=)
IL (1) IL305259A (https=)
MX (1) MX2023010183A (https=)
WO (1) WO2022187851A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12145966B2 (en) 2017-02-10 2024-11-19 University Of Louisville Research Foundation, Inc. Actinohivin variant polypeptides and methods of treatment using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012071492A1 (en) * 2010-11-23 2012-05-31 Georgia Tech Research Corporation Mir-200 family induces mesenchymal-to-epithelial transition (met) in ovarian cancer cells
EP3194973A1 (en) * 2014-09-17 2017-07-26 Institut Curie Map3k8 as a marker for selecting a patient affected with an ovarian cancer for a treatment with a mek inhibitor
US12145966B2 (en) * 2017-02-10 2024-11-19 University Of Louisville Research Foundation, Inc. Actinohivin variant polypeptides and methods of treatment using them

Also Published As

Publication number Publication date
EP4301389A1 (en) 2024-01-10
CN117098545A (zh) 2023-11-21
WO2022187851A9 (en) 2022-09-29
MX2023010183A (es) 2023-11-22
WO2022187851A1 (en) 2022-09-09
EP4301389A4 (en) 2025-03-12
AU2022229597A1 (en) 2023-10-19
IL305259A (en) 2023-10-01
JP2024509385A (ja) 2024-03-01
US20240123026A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
De Bono et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
AU2019218271B2 (en) Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies
JP2022116095A (ja) Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療
AU2018351006B2 (en) Anti-CD47 agent-based ovarian cancer therapy
WO2020041626A1 (en) Affibody proteins specific for b7-h3 (cd276)
ES2905531T3 (es) Anticuerpos anti-HER3 humano y usos de los mismos
CN114246953A (zh) 抗cMet抗体药物偶联物及其使用方法
EA022415B1 (ru) Биспецифичные молекулы, связывающие egfr/igfir
EP1581171A2 (en) Antibodies against gpr64 and uses thereof
US20200165353A1 (en) Anti-cd22 antigen binding molecules to treat lung cancer and prostate cancer
JP2022081519A (ja) Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
US20210363255A1 (en) Methods and compositions for blocking interaction between non-glycosylated pd-1 polypeptides
US20240123026A1 (en) Actinohivin Variant Polypeptides and Related Methods
JP2023506158A (ja) Ｃｄ２７６に特異的な抗体－薬物コンジュゲートおよびその使用
JP2023506187A (ja) Ｌｉｖ１－ａｄｃおよびｐｄ－１アンタゴニストとの併用療法
US20260055200A1 (en) Combination therapies
US20250296966A1 (en) Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
US20210340274A1 (en) Targeting CLPTMIL for Treatment and Prevention of Cancer
CA3017958C (en) Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties
EP4509142A1 (en) Fgfr4 as target in cancer treatment
CN119345386B (zh) 靶向Claudin18.2的抗体药物耦联物及其用途
EP3568142B1 (en) Therapeutic peptides that target tgf-beta interaction
WO2025088496A1 (en) Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
US20210017288A1 (en) Periostin antibodies and methods of using the same
HK40092156A (en) Anti-cd47 agent-based ovarian cancer therapy

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250820

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250828

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250828

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251223

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260223

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260304

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260304

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260317

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260317

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260317